I agree very professional and informative document. Highlights just how much OSL is undervalued if the product is successful. This caught my attention in the presentation - Dr Peter Knox was the previous Chief Scientific Officer for Amersham plc who developed the highly commercially successful prostate cancer localised radiation therapy or brachytherapy seeds. Amersham plc was acquired by GE Healthcare for US$3bn. Hopefully good news to come.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.030(2.59%) |
Mkt cap ! $16.49M | |||
| Open | High | Low | Value | Volume |
| $1.19 | $1.20 | $1.15 | $52.34K | 44.78K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9197 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.20 | 8746 | 2 |
View Market Depth
| Last trade - 15.45pm 30/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |